α1-Antitrypsin Z allele and risk of venous thromboembolism in the general population
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
α1-Antitrypsin Z allele and risk of venous thromboembolism in the general population. / Riis, Julie; Nordestgaard, Børge G.; Afzal, Shoaib.
In: Journal of Thrombosis and Haemostasis, Vol. 20, No. 1, 2022, p. 115-125.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - α1-Antitrypsin Z allele and risk of venous thromboembolism in the general population
AU - Riis, Julie
AU - Nordestgaard, Børge G.
AU - Afzal, Shoaib
N1 - Publisher Copyright: © 2021 International Society on Thrombosis and Haemostasis
PY - 2022
Y1 - 2022
N2 - Background: The α1-antitrypsin Z (rs28929474) allele may lead to alterations in hemostasis either through liver disease or effects on coagulation factors. Objectives: To test the hypothesis that the α1-antitrypsin Z genetic variant is associated with increased risk of venous thromboembolism. Methods: A total of 107 075 individuals from the Copenhagen General Population Study were used to test the association of the α1-antitrypsin Z genetic variant with risk of venous thromboembolism, including deep venous thrombosis and pulmonary embolism, prospectively. Confirmatory analyses were done in the UK Biobank. Results: During follow-up, venous thromboembolism was diagnosed 6649 times in noncarriers, 436 times in heterozygotes, and 10 times in homozygotes. Hazard ratios for venous thromboembolism in α1-antitrypsin Z heterozygotes and homozygotes versus noncarriers were 1.1 (95% confidence interval, 1.0–1.2) and 2.2 (1.3–3.7). A one Z allele increase was associated with a hazard ratio for venous thromboembolism of 1.2 (1.0–1.3). The corresponding odds ratio in the UK Biobank was 1.2 (1.1–1.3). The absolute risk of venous thromboembolism associated with α1-antitrypsin ZZ homozygosity was 7.8% (3.6–12.1). The corresponding estimates were 20.1% (9.1–31.2) for prothrombin G20210A and 15.0% (12.6–17.4) for factor V Leiden. The fraction of venous thromboembolic events attributable to the α1-antitrypsin Z allele was 0.7% (0.1–1.3). For the prothrombin G20210A and factor V Leiden mutations, population attributable fractions were 1.2% (0.9–1.6) and 10.5% (9.9–11.1). Conclusion: In conclusion, α1-antitrypsin ZZ homozygosity was associated with a 2.2-fold risk of venous thromboembolism and had a comparable population attributable fraction to prothrombin G20210A.
AB - Background: The α1-antitrypsin Z (rs28929474) allele may lead to alterations in hemostasis either through liver disease or effects on coagulation factors. Objectives: To test the hypothesis that the α1-antitrypsin Z genetic variant is associated with increased risk of venous thromboembolism. Methods: A total of 107 075 individuals from the Copenhagen General Population Study were used to test the association of the α1-antitrypsin Z genetic variant with risk of venous thromboembolism, including deep venous thrombosis and pulmonary embolism, prospectively. Confirmatory analyses were done in the UK Biobank. Results: During follow-up, venous thromboembolism was diagnosed 6649 times in noncarriers, 436 times in heterozygotes, and 10 times in homozygotes. Hazard ratios for venous thromboembolism in α1-antitrypsin Z heterozygotes and homozygotes versus noncarriers were 1.1 (95% confidence interval, 1.0–1.2) and 2.2 (1.3–3.7). A one Z allele increase was associated with a hazard ratio for venous thromboembolism of 1.2 (1.0–1.3). The corresponding odds ratio in the UK Biobank was 1.2 (1.1–1.3). The absolute risk of venous thromboembolism associated with α1-antitrypsin ZZ homozygosity was 7.8% (3.6–12.1). The corresponding estimates were 20.1% (9.1–31.2) for prothrombin G20210A and 15.0% (12.6–17.4) for factor V Leiden. The fraction of venous thromboembolic events attributable to the α1-antitrypsin Z allele was 0.7% (0.1–1.3). For the prothrombin G20210A and factor V Leiden mutations, population attributable fractions were 1.2% (0.9–1.6) and 10.5% (9.9–11.1). Conclusion: In conclusion, α1-antitrypsin ZZ homozygosity was associated with a 2.2-fold risk of venous thromboembolism and had a comparable population attributable fraction to prothrombin G20210A.
U2 - 10.1111/jth.15556
DO - 10.1111/jth.15556
M3 - Journal article
C2 - 34662507
AN - SCOPUS:85118372239
VL - 20
SP - 115
EP - 125
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
SN - 1538-7933
IS - 1
ER -
ID: 305691716